Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease

被引：46

作者：

Hameed, Shahul ^{[1
,2
]}

Fuh, Jong-Ling ^{[3
,4
]}

Senanarong, Vorapun ^{[5
]}

Ebenezer, Esther Gunaseli M. ^{[6
]}

Looi, Irene ^{[7
,8
]}

Dominguez, Jacqueline C. ^{[9
]}

Park, Kyung Won ^{[10
,11
]}

Karanam, Ananda Krishna ^{[12
]}

Simon, Oliver ^{[13
]}

机构：

[1] Singapore Gen Hosp, Natl Neurosci Inst, Dept Neurol, Outram Rd, Singapore, Singapore

[2] Duke NUS Med Sch, Singapore, Singapore

[3] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurol, Taipei, Taiwan

[4] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan

[5] Mahidol Univ, Siriraj Hosp, Fac Med, Div Neurol, Bangkok, Thailand

[6] Univ Kula Lumpur, Royal Coll Med Perak, Fac Med, Ipoh, Malaysia

[7] Hosp Seberang Jaya, Clin Res Ctr, George Town, Malaysia

[8] Hosp Seberang Jaya, Dept Med, George Town, Malaysia

[9] St Lukes Med Ctr, Inst Neurosci, Manila, Philippines

[10] Dong A Univ, Inst Convergence Biohlth, Coll Med, Dept Neurol, Busan, South Korea

[11] Dong A Univ, Inst Convergence Biohlth, Coll Med, Cognit Disorders & Dementia Ctr, Busan, South Korea

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Novartis Singapore Pte Ltd, Singapore, Singapore

来源：

JOURNAL OF ALZHEIMERS DISEASE REPORTS | 2020年 / 4卷 / 01期

关键词：

Alzheimer's disease; biomarker; blood; cerebrospinal fluid; early diagnosis; positron emission tomography; PLASMA NEUROFILAMENT LIGHT; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E GENOTYPE; PLACEBO-CONTROLLED TRIAL; NATIONAL INSTITUTE; DOUBLE-BLIND; ASSOCIATION WORKGROUPS; CSF BIOMARKERS; A-BETA;

D O I：

10.3233/ADR-190143

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Clinical diagnosis of Alzheimer's disease (AD) is based on symptoms; however, the challenge is to diagnose AD at the preclinical stage with the application of biomarkers and initiate early treatment (still not widely available). Currently, cerebrospinal fluid (CSF) amyloid-beta 42 (A beta(42)) and tau are used in the clinical diagnosis of AD; nevertheless, blood biomarkers (A beta(42) and tau) are less predictive. Amyloid-positron emission tomography (PET) imaging is an advancement in technology that uses approved radioactive diagnostic agents (florbetapir, flutemetamol, or florbetaben) to estimate A beta neuritic plaque density in adults with cognitive impairment evaluated for AD and other causes of cognitive decline. There is no cure for AD to date-the disease progression cannot be stopped or reversed; approved pharmacological agents (donepezil, galantamine, and rivastigmine; memantine) provide symptomatic treatment. However, the disease-modifying therapies are promising; aducanumab and CAD106 are in phase III trials for the early stages of AD. In conclusion, core CSF biomarkers reflect pathophysiology of AD in the early and late stages; the application of approved radiotracers have potential in amyloid-PET brain imaging to detect early AD.

引用

页码：21 / 37

页数：17

共 132 条

[1] Aβ, tau and ApoE4 in Alzheimer's disease:: the axonal connect ion [J].